- Too hot by day, Dubai's floodlit beaches are packed at night
- Is music finally reckoning with #MeToo?
- Fans hail Trump's 'guts' as he returns to site of rally shooting
- Lebanon state media says 'very violent' Israeli strikes hit south Beirut
- Guardians maul Tigers, miracle Mets rally in MLB series openers
- Lebanon state media says Israeli strikes hit south Beirut
- Miami on track for MLS record points after win in Toronto
- Madrid beat Villarreal but Carvajal suffers knee injury
- Madrid beat Villarreal to move level with Liga leaders Barcelona
- Monaco take top spot in Ligue 1 with win at Rennes
- French rugby player on rape charge whistled but 'serene' on return
- Madrid beat Villarreal to level Liga leaders Barca
- Thuram treble fires Inter past Torino and up to second
- 'Fight': defiant Trump jets in to site of rally shooting
- Toddler among 3 dead in migrant Channel crossings
- Mexico City's new mayor sworn in with pledges on water, housing
- Israel on alert ahead of Hamas attack anniversary
- Guardians maul Tigers in MLB playoff series opener
- Macron criticises Israel on Gaza, Lebanon operations
- French rugby player whistled but 'serene' on return amid ongoing rape case
- Kovacic stars as Man City sink Fulham to get title bid back on track
- Retegui hat-trick fires five-star Atalanta to hammering of Genoa
- Heavyweights Australia, England off to World Cup winning starts
- Visiting UN refugee agency chief decries 'terrible crisis' in Lebanon
- Spinners come to party as England defeat Bangladesh at T20 World Cup
- Search continues for missing in deadly Bosnia floods
- Man City sink Fulham to get title bid back on track
- France's Auradou whistled on Pau return in Perpignan loss amid ongoing rape case
- A 'forgotten' valley in storm-hit North Carolina, desperate for help
- Arsenal hit back in style after Southampton scare
- Thousands march for Palestinians ahead of Oct 7 anniversary
- Hezbollah heir apparent Safieddine out of contact after strikes
- Liverpool stay top of Premier League as Arsenal, Man City win
- In dank Tour of Emilia, Pogacar shines in rainbow jersey
- DR Congo launches mpox vaccination drive, hoping to curb outbreak
- Trump returns to site of failed assassination
- Careless Leverkusen held to Bundesliga draw
- O'Brien's 'superstar' Kyprios posts landmark win on Arc weekend
- Toddler crushed to death in migrant Channel crossing
- Liverpool suffer Alisson injury blow
- Habosi helps Racing beat Vannes before Auradou's playing return
- Thousands march in London in support of Palestinians, 1 year after Oct 7
- Israel readying response to Iran missile attack
- Schutt, Mooney help Australia beat Sri Lanka in Women's T20 World Cup
- Liverpool extend Premier League lead with win at Palace
- Djokovic 'shakes rust off' to make third round of Shanghai Masters
- 'Imperfect' PSG fighting on all fronts - Luis Enrique
- Struggling Pakistan look to thwart adaptable England
- Child 'trampled to death' in asylum seekers' Channel crossing: minister
- Gauff fights back to set up Beijing final against Muchova
European medicines watchdog rejects new Alzheimer's drug
Europe's medicines watchdog on Friday rejected a marketing request for a new Alzheimer's disease treatment, saying the risks of the medicine's side effects, including potential brain bleeding, outweighed the benefits.
The decision by the Amsterdam-based European Medicines Agency was met with dismay, but experts said effective treatment for the degenerative mental disease affecting millions in Europe alone, was getting closer.
"The CHMP recommended not granting a marketing authorisation for Leqembi, a medicine intended for the treatment of Alzheimer's disease," the European Medicines Agency said, referring to its committee for evaluating drugs for human use.
Leqembi, which was developed by US multinational Biogen and Japanese-based Eisai, is the brand name of an active substance called lecanemab, which is used to treat adults with mild memory and cognitive problems resulting from the early stages of the common type of dementia.
But the CHMP said "the observed effect of Leqembi on delaying cognitive decline does not counterbalance the risk of serious side events associated with the medicine."
"The most important safety concern with Leqembi is the frequent occurrence of amyloid-related imaging abnormalities (ARIA), a side effect, seen in brain imaging, that involves swelling and potential bleedings in the brain," the EMA said.
- 'Unmet need' -
Leqembi is a monoclonal antibody, a type of protein that clings to a substance in the brain and can delay worsening of the disease. It is given intravenously every two weeks.
Leqembi, together with another Alzheimer's drug called Aduhelm -- also developed by Biogen and Eisai -- received approval from the US Food and Drug Administration (FDA) early last year.
Both drugs were approved through an accelerated process by the FDA for drugs treating serious conditions where there is an unmet medical need.
But in late January this year, Biogen pulled the controversial Aduhelm from the market, saying it was focusing on Leqembi instead.
Preliminary data from a trial of Leqembi was released in September 2022 and found it slowed cognitive decline in Alzheimer's patients by 27 percent.
Around eight million people in the European Union live with dementia, with Alzheimer's disease accounting for more than half of these cases, according to the Alzheimer Europe website.
Eisai, in a statement, said it was "extremely disappointed with the CHMP's negative opinion".
"There is a significant unmet need for new innovative treatment options that target an underlying cause of disease progression," Eisai's chief clinical officer Lynn Kramer said.
Eisai said it would seek a re-examination of the EMA's opinion "to ensure this treatment is available for eligible people living with early Alzheimer's disease in the EU as soon as possible."
The EMA said Eisai presented a main study involving 1,795 people with early Alzheimer's who either received Leqembi or a placebo, measured over a span of 18 months.
Eisai said that the watchdog added that its refusal had "no consequences for patients in clinical trials with Leqembi".
Eisai may now ask for a re-examination within 15 days, the EMA said.
- 'Ramp up efforts' -
Experts voiced disappointment at the EMA's refusal, but added there were "reasons to remain hopeful".
"Lecanemab has shown that it is possible to slow down disease progression, and research does work," said Tara Spires-Jones, president of the British Neuroscience Association.
"Now we need to ramp up our efforts to discover new and safer treatments," she said in a statement, adding that "each discovery brings us closer to new and better treatments."
Bart De Strooper, a professor in Alzheimer's disease at the University College London called the EMA's decision "unfortunate yet not unexpected".
"This conservative approach means that patients and doctors eager to explore a proven effective drug are now denied access," he said in a statement.
"With no current therapies available, it's disheartening to think that if we had applied such caution in the past, particularly with cancer drugs and their severe side effects, we might still be without cancer treatments today," De Strooper said.
J.Oliveira--AMWN